Skip to main content
SpringerLink
Log in
Book cover

Current Advances in Osteosarcoma pp 161–177Cite as

HER-2 Involvement in Osteosarcoma

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 804))

Abstract

The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the finding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous conflicting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312(5994):513–516

    Article  PubMed  CAS  Google Scholar 

  2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730):1132–1139

    Article  PubMed  CAS  Google Scholar 

  3. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 82(19):6497–6501

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717):974–976

    Article  PubMed  CAS  Google Scholar 

  5. Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319(6050):226–230. doi:10.1038/319226a0

    Article  PubMed  CAS  Google Scholar 

  6. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394–398. doi:10.1038/378394a0

    Article  PubMed  CAS  Google Scholar 

  7. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99(13):8880–8885. doi:10.1073/pnas.122249299

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Schroeder JA, Lee DC (1998) Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Differ 9(6):451–464

    PubMed  CAS  Google Scholar 

  9. Jones FE, Stern DF (1999) Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18(23):3481–3490. doi:10.1038/sj.onc.1202698

    Article  PubMed  CAS  Google Scholar 

  10. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, Riethmacher D (1998) The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev 12(12):1825–1836

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Morris JK, Lin W, Hauser C, Marchuk Y, Getman D, Lee KF (1999) Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron 23(2):273–283

    Article  PubMed  CAS  Google Scholar 

  12. Park SK, Miller R, Krane I, Vartanian T (2001) The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J Cell Biol 154(6):1245–1258. doi:10.1083/jcb.200104025

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16(7):1647–1655. doi:10.1093/emboj/16.7.1647

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21(2):177–184. doi:10.1016/j.ceb.2008.12.010

    Article  PubMed  CAS  Google Scholar 

  15. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167. doi:10.1093/emboj/19.13.3159

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3 T3 cells. Science 237(4811):178–182

    Article  PubMed  Google Scholar 

  17. Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3 T3 cells. Proc Natl Acad Sci U S A 84(20):7159–7163

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89(22):10578–10582

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4(1):19–26

    PubMed  CAS  Google Scholar 

  20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182

    Article  PubMed  CAS  Google Scholar 

  21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

    Article  PubMed  CAS  Google Scholar 

  22. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13):2825–2831

    PubMed  CAS  Google Scholar 

  23. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737–744

    PubMed  CAS  Google Scholar 

  24. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8):2659–2671

    PubMed  CAS  Google Scholar 

  25. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101

    Article  PubMed  CAS  Google Scholar 

  26. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi:10.1056/NEJMoa052122

    Article  PubMed  CAS  Google Scholar 

  27. Press MF, Hung G, Godolphin W, Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54(10):2771–2777

    PubMed  CAS  Google Scholar 

  28. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215–1221

    Article  PubMed  CAS  Google Scholar 

  29. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64(6):2047–2053

    Article  PubMed  CAS  Google Scholar 

  30. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, Geller DS (2012) Cell surface receptor expression patterns in osteosarcoma. Cancer 118(3):740–749. doi:10.1002/cncr.26339

    Article  PubMed  CAS  Google Scholar 

  31. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P, Serra M (2005) Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer 41(9):1349–1361. doi:10.1016/j.ejca.2005.03.015

    Article  PubMed  CAS  Google Scholar 

  32. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77(1):71–78. doi:10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5

    Article  PubMed  CAS  Google Scholar 

  33. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458

    PubMed  CAS  Google Scholar 

  34. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781–2788

    PubMed  CAS  Google Scholar 

  35. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25(1):27–32

    Article  PubMed  Google Scholar 

  36. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M (1998) Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55(6):548–555

    Article  PubMed  CAS  Google Scholar 

  37. Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch D (2004) Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 84(1):113–121. doi:10.1038/sj.labinvest.3700006

    Article  PubMed  CAS  Google Scholar 

  38. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, Versari M, Bacci G (2004) Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100(9):1936–1942. doi:10.1002/cncr.20151

    Article  PubMed  CAS  Google Scholar 

  39. Maitra A, Wanzer D, Weinberg AG, Ashfaq R (2001) Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92(3):677–683

    Article  PubMed  CAS  Google Scholar 

  40. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, Bos GD (2001) Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14(12):1277–1283. doi:10.1038/modpathol.3880474

    Article  PubMed  CAS  Google Scholar 

  41. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L (2002) Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res 8(3):788–793

    PubMed  CAS  Google Scholar 

  42. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM, Hogendoorn PC (2004) Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40(7):963–970. doi:10.1016/j.ejca.2003.10.025

    Article  PubMed  CAS  Google Scholar 

  43. Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M (2004) HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 22(1):16–24

    Article  PubMed  CAS  Google Scholar 

  44. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS (2005) HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 8(5):525–532. doi:10.1007/s10024-005-0044-5

    Article  PubMed  CAS  Google Scholar 

  45. Willmore-Payne C, Holden JA, Zhou H, Gupta D, Hirschowitz S, Wittwer CT, Layfield LJ (2006) Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 130(5):691–698. doi:10.1043/1543-2165(2006)130[691:EONGSI]2.0.CO;2

    PubMed  CAS  Google Scholar 

  46. Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S (2009) Her-2/neu, p-53, and their coexpression in osteosarcoma. J Pediatr Hematol Oncol 31(4):245–251. doi:10.1097/MPH.0b013e318197947e

    Article  PubMed  CAS  Google Scholar 

  47. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S, Ishii S (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94(5):1397–1404

    Article  PubMed  CAS  Google Scholar 

  48. Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S (2001) Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 60(4):361–366, doi:58533

    Article  PubMed  CAS  Google Scholar 

  49. Li YG, Geng X (2010) A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care 19(3):313–316. doi:10.1111/j.1365-2354.2008.00970.x

    Article  CAS  Google Scholar 

  50. Gorlick R, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gorlick S, Gill J, Geller D, Randall RL, Janeway KA, Schwartz CL, Grier H, Meyers P, Bernstein M, Marina N (2012) HER-2 expression is not prognostic in osteosarcoma: A report of a Children’s Oncology Group Prospective Biology Study. Connective Tissue Oncology Society, 2012 meeing abstract

    Google Scholar 

  51. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP, Ferguson WS, Letson GD, Marcus K, Goorin A, Beardsley P, Marina N (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30(20):2545–2551. doi:10.1200/JCO.2011.37.4546

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Montefiore Medical Center, The Children’s Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd Floor, Bronx, NY, USA

    Jonathan Gill M.D. & Richard Gorlick M.D.

  2. The Albert Einstein College of Medicine, Bronx, NY, USA

    Jonathan Gill M.D., David Geller M.D. & Richard Gorlick M.D.

  3. Department of Orthopedic Surgery, Montefiore Medical Center and The Children’s Hospital at Montefiore, Bronx, NY, USA

    David Geller M.D.

Authors
  1. Jonathan Gill M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Geller M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Gorlick M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Gorlick M.D. .

Editor information

Editors and Affiliations

  1. Division of Pediatrics, Department of Cancer Biology, The Mary V. and John A. Reilly Distinguished Chair, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Eugenie S. Kleinerman, M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gill, J., Geller, D., Gorlick, R. (2014). HER-2 Involvement in Osteosarcoma. In: Kleinerman, M.D., E. (eds) Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, vol 804. Springer, Cham. https://doi.org/10.1007/978-3-319-04843-7_9

Download citation

Publish with us

Policies and ethics

Search

Navigation